Daewoong Advances Clinical Education in Aesthetic Medicine with Nabota-Focused Training at 'AMUSE 2025' … Launches Comprehensive 'DEEP' Expert Education Program for Indonesian Medical Professionals
(Jakarta, June 30th, 2025)
Daewoong Pharmaceutical, in collaboration with CGBIO Indonesia, participated in the international aesthetic medicine congress ‘AMUSE 2025 (Aesthetic Medicine Updates Seminar and Exhibition)’, held in Jakarta and Tangerang, Indonesia, from June 17 to 22, 2025. During the event, the companies showcased a comprehensive combination procedure education program centered on their high-purity botulinum toxin ‘Nabota’, garnering strong interest from local medical professionals.
Hosted by the Jakarta Science Academy, AMUSE 2025 brought together over 1,200 doctors, including dermatologists, plastic surgeons, and other aesthetic experts.
At the joint Daewoong-CGBIO Indonesia exhibition booth, operated under the vision ‘Move to NEW GEN’, reflecting their commitment to leading the next generation of the aesthetic industry, attendees explored the companies’ flagship aesthetic products, including ▲Nabota, the high-purity botulinum toxin; ▲Facetem, the calcium hydroxyapatite (CaHA)-based skin booster; ▲DCLASSY, the premium hyaluronic acid (HA) filler; and ▲LUXX, the polydioxanone (PDO) suture thread.
This initiative was led by KIIMOT (Korea-Indonesia Integrated Marketing Operation Taskforce), a newly established joint marketing taskforce between Daewoong Pharmaceutical and CGBIO Indonesia. Under KIIMOT, the companies will continue to operate the ‘DEEP (Daewoong Expert Education Program)’, a structured education program designed to enhance product understanding, procedural skills, and clinical experience among Korean and Indonesian medical professionals.
Following the program’s soft launch at the WeSWAM congress in April, participation in AMUSE 2025 further expanded DEEP’s on-site, customized combination procedure training, tailored specifically to the needs of Indonesian medical professionals.
Live workshops and lectures were conducted by leading Korean aesthetic experts who also serve as global Key Opinion Leaders (KOLs) for Nabota. Dr. Kyung-tae Bae, Director of It's Me Clinic (Sejong Branch), performed live demonstrations of lower face lifting and masseter hypertrophy procedures using Nabota. Dr. Jae-yoon Jung, Director of Oaro Dermatology (Nowon Branch), delivered lectures on combination treatment strategies involving Nabota and Facetem.
Dr. Kyung-tae Bae commented, “Nabota's biggest advantage is its rapid onset and long duration. It was meaningful to share practical injection techniques with Indonesian peers.” Dr. Jae-yoon Jung added, “This session was a valuable opportunity to introduce patient-customized combination procedure methods that can improve treatment outcomes."
Changwoo Ha, Head of the Aesthetic Business Division at KIIMOT, emphasized, “Leveraging Daewoong and CGBIO’s globally recognized aesthetic pipeline, we will continue to localize and advance combined procedure strategies suited to the Indonesian market. Through the DEEP education program, we aim to foster sustainable, expert-level training for local professionals.”
Meanwhile, Daewoong Pharmaceutical plans to officially launch Nabota in Indonesia this July. Through KIIMOT's integrated marketing efforts, centered around combination procedures, the company aims to enhance awareness of Nabota, Facetem, and other products in its aesthetic pipeline.
# # #
